Science Explorer Back to mapMap
Discussion
Company · Newark · United States

CymaBay Therapeutics (United States)

Research works
12
▲ 68% vs 2018-21
Citations
192
15.4 per fractional work
Top-10% rate
21.7%
all institutions 10.0%
Open access
50%
world 40%
International
40%
world 18%

Not ranked overall: CymaBay Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does CymaBay Therapeutics (United States) work in?

In all years, 57% of research at CymaBay Therapeutics (United States) is in Health Sciences, 33% in Life Sciences. Its largest fields are Medicine (55%), Biochemistry, Genetics and Molecular Biology (22%), Pharmacology, Toxicology and Pharmaceutics (8%). It does 1.7× the world's share of Health Sciences.

Health Sciences: 7 fractional works · 56.9% of its workMedicine: 7 fractional works · 55.2% of its workEpidemiology: 1 fractional works · 11.4% of its workNephrology: 1 fractional works · 7.6% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 7.4% of its workHepatology: 1 fractional works · 6.6% of its workOncology: 1 fractional works · 6.5% of its workSurgery: 1 fractional works · 6.1% of its workPulmonary and Respiratory Medicine: 1 fractional works · 4.2% of its workPhysiology: 0 fractional works · 3.5% of its workPathology and Forensic Medicine: 0 fractional works · 0.7% of its workDermatology: 0 fractional works · 0.6% of its workRheumatology: 0 fractional works · 0.4% of its workNursing: 0 fractional works · 1.8% of its workNutrition and Dietetics: 0 fractional works · 1.8% of its workLife Sciences: 4 fractional works · 33.4% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 22.1% of its workMolecular Biology: 1 fractional works · 9.6% of its workBiotechnology: 1 fractional works · 5.6% of its workGenetics: 0 fractional works · 3.0% of its workCancer Research: 0 fractional works · 1.4% of its workCell Biology: 0 fractional works · 1.4% of its workClinical Biochemistry: 0 fractional works · 1.4% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 8.2% of its workPharmacology: 1 fractional works · 8.2% of its workImmunology and Microbiology: 0 fractional works · 3.1% of its workImmunology: 0 fractional works · 3.1% of its workSocial Sciences: 1 fractional works · 5.5% of its workEconomics, Econometrics and Finance: 0 fractional works · 2.7% of its workEconomics and Econometrics: 0 fractional works · 2.7% of its workSocial Sciences: 0 fractional works · 1.9% of its workPolitical Science and International Relations: 0 fractional works · 1.0% of its workAnthropology: 0 fractional works · 0.9% of its workPsychology: 0 fractional works · 0.9% of its workSocial Psychology: 0 fractional works · 0.9% of its workPhysical Sciences: 1 fractional works · 4.2% of its workEngineering: 0 fractional works · 2.7% of its workBiomedical Engineering: 0 fractional works · 2.7% of its workMaterials Science: 0 fractional works · 1.4% of its workBiomaterials: 0 fractional works · 1.4% of its workChemistry: 0 fractional works · 0.2% of its workALL ITS WORKCymaBayTherapeutics…12fractional works, all years
Life Sciences33%Physical Sciences4%Health Sciences57%Social Sciences5%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 11 fields, with their numbers
    1. Medicine755.2%
    2. Nursing01.8%
    1. Biochemistry, Genetics and Molecular Biology322.1%
    2. Pharmacology, Toxicology and Pharmaceutics18.2%
    3. Immunology and Microbiology03.1%
    1. Economics, Econometrics and Finance02.7%
    2. Social Sciences01.9%
    3. Psychology00.9%
    1. Engineering02.7%
    2. Materials Science01.4%
    3. Chemistry00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 5.06× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 4.33× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 0.96× its world share, 0 worksPharmacology, Toxico…Engineering: 0.23× its world share, 0 worksEngineeringMedicine: 3.36× its world share, 3 worksMedicineSocial Sciences: 0.03× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.1×. Every wedge is a field page.

All 6 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology5.06×1 works
  2. Immunology and Microbiology4.33×0 works
  3. Medicine3.36×3 works
  4. Pharmacology, Toxicology and Pharmaceutics0.96×0 works
  5. Engineering0.23×0 works
  6. Social Sciences0.03×0 works

Who are the top researchers at CymaBay Therapeutics (United States)?

Ranked on the quality score, Charles A. McWherter and Alexandra S. Steinberg lead among researchers whose main affiliation is CymaBay Therapeutics (United States).

  1. 1 Charles A. McWherter United States · #721,076 worldwide 2.7k citations · 101 works
  2. 2 Alexandra S. Steinberg United States · #1,072,590 worldwide 746 citations · 43 works
All ranked researchers at CymaBay Therapeutics (United States)

What are the most cited papers from CymaBay Therapeutics (United States)?

The most cited paper from CymaBay Therapeutics (United States) is "Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study" (Derralynn A. Hughes et al., 2016), with 395 citations. Next come "Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study" (191) and "Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study" (125).

All 36 most cited papers, with filters and sorting

Which research topics does CymaBay Therapeutics (United States) publish most on?

By volume in 2022-now: Liver Disease Diagnosis and Treatment, Drug Transport and Resistance Mechanisms, Liver Diseases and Immunity and Peroxisome Proliferator-Activated Receptors.

  1. 1 Liver Disease Diagnosis and Treatment Epidemiology 1 works
  2. 2 Drug Transport and Resistance Mechanisms Oncology 1 works
  3. 3 Liver Diseases and Immunity Hepatology 0 works
  4. 4 Peroxisome Proliferator-Activated Receptors Molecular Biology 0 works
  5. 5 Cancer Research and Treatments Biotechnology 0 works
  6. 6 Pediatric Hepatobiliary Diseases and Treatments Surgery 0 works
  7. 7 Gallbladder and Bile Duct Disorders Pulmonary and Respiratory Medicine 0 works
  8. 8 Virus-based gene therapy research Genetics 0 works
  9. 9 Aldose Reductase and Taurine Cell Biology 0 works
  10. 10 interferon and immune responses Immunology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available50.5%not open49.5%

World: 40% of research is openly available.

with international co-authors40.3%domestic only59.7%

World: 18% is written across borders.

How has CymaBay Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 68% higher than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is CymaBay Therapeutics (United States) as a percentage of every work published that year, 0.000018% in 2023.

still counting0.000025%0.000050%0.000075%CymaBay Therapeutics (United States)0.000035% in 202520102020

Fractional works of CymaBay Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Newark

All research institutions in Newark

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about CymaBay Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.